|
|
|
Indaptus Therapeutics Inc (NASDAQ: INDP) |
|
Indaptus Therapeutics Inc
Officers & Directors
Robert E. Martell, M.D., Ph.D. - Director Mark J. Gilbert - Director Jeffrey A. Meckler - Chief Executive Officer and Director Anthony J. Maddaluna - Director Michal J. Newman, Ph.D. - Chief Scientific Officer and Director Roger J. Pomerantz, M.D. - Chairman of the Board of Directors Nir Sassi - Chief Financial Officer William B. Hayes - Director Hila Karah - Director,
Indaptus Therapeutics Inc currently has 5 employees.
News about Indaptus Therapeutics Inc Key Personnel |
Indaptus Therapeutics Inc. a leader in immunotherapy innovation, has made significant strides with its cutting-edge Decoy platform, which focuses on combating cancer through novel immunotherapeutic approaches. Recently, the company published preclinical data in the peer-reviewed journal Frontiers in Immunology , shedding light on the single-agent anti-tumor activity of their Decoy platform. This data also underscores the potential for combination therapies that include non-steroidal anti-inflammatory drugs (NSAIDs), anti-PD1 checkpoint inhibitors, low-dose chemotherapy (LDC), and targeted antibody therapies. These findings could herald a transformative shift in how immunotherapy is approached and applied in...
|
Indaptus Therapeutics, Inc. Secures $3.0 Million in Funding for Groundbreaking Cancer and Viral Infection Treatments
August 7, 2024 - Indaptus Therapeutics, Inc. (Nasdaq: INDP), a pioneering clinical stage biotechnology company, announced today the successful completion of a $3.0 million registered direct offering and concurrent private placement. This funding milestone underscores Indaptus commitment to revolutionizing cancer and viral infection treatments through innovative therapies.
Under securities purchase agreements, Indaptus has secured investments from various investors, including one of its own officers, totaling 1,643,837 shares of common stock. Additionally, the company has agreed to is...
|
Introduction
Indaptus Therapeutics Inc, a leading biopharmaceutical company in the healthcare sector, is set to present the initial clinical data on their lead product candidate, Decoy20, at the upcoming STING and TLR-Targeted Therapies Summit. Dr. Newman, Chief Scientific Officer at Indaptus, will shed light on the latest findings that further validate the company s Pulse-Prime hypothesis. This announcement comes at a pivotal time for Indaptus, as the stock recently experienced a significant surge in value.
Indaptus Stock Performance and Financials
In May 2024, Indaptus Therapeutics Inc witnessed a remarkable 15.49% increase in its stock prices. This surge in value reflects a growing inves...
|
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.
